<DOC>
	<DOC>NCT02910557</DOC>
	<brief_summary>A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients</brief_summary>
	<brief_title>Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient has provided written informed consent Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma Patient has a prior history of being a subject in an interventional clinical trial for IMLYGIC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CTCAE - Common Terminology Criteria for Adverse Events</keyword>
	<keyword>eCRF - electronic case report form</keyword>
	<keyword>ECOG - Eastern Cooperative Oncology Group</keyword>
	<keyword>EDC - electronic data capture</keyword>
	<keyword>GM-CSF - human granulocyte macrophage colony-stimulating factor</keyword>
	<keyword>HCP - health care provider</keyword>
	<keyword>HSV-1 - herpes simplex virus type 1</keyword>
	<keyword>ICF - informed consent form</keyword>
	<keyword>ICP - infected cell protein</keyword>
	<keyword>IEC - Independent Ethics Committee</keyword>
	<keyword>IRB - Institutional Review Board</keyword>
	<keyword>MedDRA - Medical Dictionary for Regulatory Activities</keyword>
	<keyword>PFU - plaque-forming unit</keyword>
	<keyword>qPCR - quantitative polymerase chain reaction</keyword>
	<keyword>SmPC - Summary of Product Characteristics</keyword>
	<keyword>USPI - United States Prescribing Information</keyword>
</DOC>